New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
16:25 EDTDMND, TSN, GSK, INTC, LRN, LGND, LOWOn The Fly: Closing Wrap
Stocks on Wall Street were higher after the averages all advanced sharply at the open and maintained gains through the trading day. Optimism about hopes for a resolution to the fiscal cliff helped push stocks into positive territory Friday and that positive momentum carried over as the new week began. Positive economic data from the National Association of Realtors also buoyed investor confidence on the day... ECONOMIC EVENTS: In the U.S., the National Association of Realtors said that resales of existing homes climbed 2.1% last month to a seasonally adjusted annual rate of 4.79M units, beating forecasts for sales to have declined 0.2% from the prior month. The housing market index for November, a barometer of homebuilder sentiment, rose to 46, versus expectations for a flat 41 reading... COMPANY NEWS: Lowe's (LOW) reported earnings per share with charges that met expectations and revenue that beat consensus, sending shares higher $1.98, or 6.19%, to $33.96... Intel's (INTC) CEO Paul Otellini announced plans to retire in May and shares leveled off after some early day volatility, ending up 6c, or 0.30%, to $20.25... MAJOR MOVERS: Among the notable gainers was Tyson Foods (TSN), advancing $1.84, or 10.90%, to $18.72 after its quarterly earnings beat consensus and the company raised its regular dividend and declared a special dividend. Also higher were shares of Ligan Pharmaceuticals (LGND), up $2.40, or 14.40%, to $19.07 after the company's partner GlaxoSmithKline (GSK) said the FDA approved a new indication for its supportive care treatment for a condition associated with chronic hepatitis C. Among noteworthy losers was (DMND), down $1.79 or 11.83%, to $13.34 after the stock was downgraded to Underperform from Hold at Jeffries. Also lower were shares of K12 (LRN), down $3.84, or 18.78%, to $16.61 following a downgrade to Market Perform at Wells Fargo prompted by issues at one of its schools in Colorado. The company said in a midday release that it has been working "for some time" with Colorado Virtual Academy to address the performance issues that have arisen there... INDICES: The Dow was up 207.65, or 1.65%, to 12,795.96; the Nasdaq was up 62.94, or 2.21%, to 2,916.07; and the S&P 500 was up 27.01, or 1.99%, to 1,386.89.
News For LOW;INTC;TSN;LGND;GSK;DMND;LRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
February 2, 2016
18:01 EDTINTCIntel upgraded to Neutral from Sell at Goldman
Subscribe for More Information
12:15 EDTTSNTyson Foods closes some pork and beef plants due to blizzard, Reuters reports
Subscribe for More Information
09:01 EDTLGNDLigand enters into OmniAb platform license pact with Tizona
Ligand Pharmaceuticals announced it has entered into a worldwide license agreement with Tizona Therapeutics, Inc. Under the license, Tizona will use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies. Ligand will be eligible to receive annual platform access payments as well as patent filing fees, clinical milestone payments and royalties for each successful OmniAb antibody. Tizona will be responsible for all costs related to the program.
08:17 EDTGSKAdaptimmune, GSK expand strategic immunotherapy collaboration
Adaptimmune Therapeutics (ADAP) and GlaxoSmithKline (GSK) announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune's lead clinical cancer program, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1, toward pivotal trials in synovial sarcoma. Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program. GSK has an option on the NY-ESO-1 program through clinical proof of concept and, on exercise, will assume full responsibility for the program.
07:42 EDTGSKPressure mounts on big pharma names to shrink, sharpen focus, FT says
Subscribe for More Information
06:32 EDTGSKGSK, J&J back Index Ventures' $1B biotech business spinoff, Reuters says
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) will back a new spinoff from Index Ventures, which is spinning off its biotech portfolio into a new $1B entity, Reuters reports. The New Medicxi Ventures business will be helmed by the existing life sciences team from Index and will include all the current biotech portfolio firms, the report says. Medicxi raises $229M for a new fund in Europe with GSK and J&J each putting in 25%, Reuters reports. Reference Link
February 1, 2016
10:51 EDTINTCActive calls; INTC CVS TWTR APC BAC
Subscribe for More Information
09:36 EDTINTCActive equity options trading on open
Active equity options trading on open: BAC AAPL FB AMZN TWTR MGM MCD NFLX GILD INTC TSLA AA BABA C
January 29, 2016
16:12 EDTLOWLowe's names Sandra Cochran to board of directors
Subscribe for More Information
07:03 EDTINTCProofpoint results suggest demand remains strong, says Piper Jaffray
Subscribe for More Information
January 28, 2016
07:33 EDTLRNK12 sees Q3 revenue $215M-$225M, consensus $215.44M
07:32 EDTLRNK12 reports Q2 EPS 23c, consensus 22c
Subscribe for More Information
January 27, 2016
08:37 EDTLRNK12 appoints Stuart Udell as CEO
K12 announced that the company has named Stuart Udell as the company's CEO. The appointment will become effective on February 8. Nate Davis, current chairman and CEO, will remain active in the business as the Executive Chairman of K12's board.
07:04 EDTINTCThe Deal to hold a virtual roundtable
The "Internet of Things: Dealmaking" roundtable discussion about opportunities in IoT which is driving growth and M&A in sectors from telecom, software groups and device makers, will be held on January 27 at 1 pm. Webcast Link
January 26, 2016
05:15 EDTINTCStocks with implied volatility below IV index mean; AXP INTC
Stocks with implied volatility below IV index mean; American Express (AXP) 28, Intel (INTC) 27 according to iVolatility.
January 25, 2016
11:05 EDTGSKOncoMed price target lowered to $29 from $43 at Piper Jaffray
Subscribe for More Information
09:32 EDTINTCApple Active equity options trading on open
Subscribe for More Information
07:16 EDTINTCIntel upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Deepon Nag upgraded Intel to Oupterform and raised his price target to $35 from $34 on shares. The analyst believes the combination of easier comps and moderating competition in tablets and smartphones should result in a PC shipment growth acceleration into CY16. Additionally, Nag said Intel has been undershipping end-demand for all of 2015, which adds to estimates and potential upside as the PC supply chain replenishes inventories.
06:53 EDTGSKGlaxo, Astra, J&J partner with universities in drug research fund, Reuters says
Subscribe for More Information
05:36 EDTINTCStocks with implied volatility below IV index mean; CELG INTC
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use